Cover Image

NPS+:乾癬 (美國)

NPS+ Psoriasis (US)

出版商 FirstWord 商品編碼 358499
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
NPS+:乾癬 (美國) NPS+ Psoriasis (US)
出版日期: 2016年04月01日 內容資訊: 英文

從進行了本報告提供美國的100名的皮膚科醫生為對象調查的結果,支援稱乾癬的領導品牌藥的醫生的使用趨勢和比較·來分析各種見解,客戶的忠誠度(權利金)的NPS (淨推薦值) 指標的改善。


  • Stelara (Ustekinumab:Janssen Biotech)
  • Humira (Adalimumab:AbbVie)
  • Enbrel (Etanercept:Amgen)
  • Cosentyx (sekukinumabu:Novartis)
  • Otezla (apremilast:Celgene)
  • Remicade (Infliximab:Janssen Biotech)


  • 乾癬市場的滿意度
  • 醫生對特定品牌藥的忠誠度等級
  • 特定品牌推薦者推薦的其他品牌數
  • 特定品牌推薦者、批判者推薦的其他品牌
  • 在推薦者及批判者間的特定品牌的市場佔有率
  • 如果批判者成為推薦者可獲得的市場佔有率
  • 推薦者、中立者 (被動)、批判者和特定品牌相關的訊息
  • 品牌DNA:醫生本身對特定品牌藥相關的話
Product Code: 596200651

Psoriasis: Low loyalty levels & high competition, how does your brand stack up?

Physicians in the psoriasis market are showing decidedly low levels of loyalty, but high levels of satisfaction among the available brands. Find out what brand messages are being associated with your brand, what effect they have on physicians' recommendations, and, critically, how your brand compares to your competitors.

FirstView's ‘NPS+ Psoriasis’ report compares brand loyalty for 6 major psoriasis treatments-information you can use to improve your brand's health, and boost your market share.

Based on your net promoter score (NPS), the report shows you how likely doctors are to recommend your brand-and your competitors. A detailed breakdown of brand associations helps you see which marketing messages are likely to succeed, while a unique “Brand DNA” section reveals doctors' candid thoughts about your brand.

Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear.

Get Answers to Key Questions about Psoriasis Treatments

  • Stelara (ustekinumab; Janssen Biotech): Are physicians considering another brand as interchangeable with Stelara?
  • Humira (adalimumab; AbbVie): Neck & neck with a key competitor, does the route of administration involved in prescribing Humira stop physicians from recommending it?
  • Enbrel (etanercept; Amgen): Several promoters state that this is a safe & reliable brand, but what factors are creating a number of concerns?
  • Cosentyx (secukinumab; Novartis): Cosentyx & Enbrel have a similar NPS, but which brand would gain more by converting their 'passive prescribers' to 'promoters'?
  • Otezla (apremilast; Celgene): Otezla is being described as having a novel MOA, but what effect is this actually having on its NPS?
  • Remicade (infliximab; Janssen Biotech): Do the number of passive physicians represent an opportunity for Remicade to increase its NPS?

Top Takeaways

  • Top two brands lead with significantly higher NPS: However, the percentage of promoters across all the treatments would suggest a different outcome.
  • Physicians true opinions revealed: See verbatim copies of what messages physicians associate with your brand, both positive and negative
  • Increased loyalty could improve commercial results: Brands show low to very low levels of loyalty, examining why this is could lead to a significant commercial advantage.
  • Several brands have significant opportunities for NPS growth: Several brands will dramatically increase their score by turning their detractive & passive physicians into promoters.
  • Drug delivery method key to success or failure for many: The scores for three drugs are dramatically affected, either positively or negatively, by their mechanism of action.
  • Satisfaction doesn't ensure exclusivity: Majority of physicians are satisfied with the treatments available, but even with this satisfaction level, less than 20% of physicians show consistent prescription choices.
  • Quality of life is top of mind for many prescribers: Physicians report that QoL is a key consideration for 4 out of 6 available brands when deciding whether or not to recommend it
  • Low considerations of cost: A combination of the long term effects on patients & the benefit/risk profile take the top spots for impacting on recommendations, whereas cost never makes it into the top four.

A Report Based on Expert Knowledge

We surveyed 100 US dermatologists chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between March 2nd and March 16th, 2016.

Explore Important Brand Loyalty Issues

NPS+ Psoriasis (US) explores key issues affecting brand loyalty for psoriasis drug manufacturers. You'll learn:

  • How satisfied the psoriasis market is.
  • How loyal doctors are to your brand.
  • How many other brands your promoters recommended.
  • Which other brands your promoters and detractors recommend.
  • How much market share your brand has among promoters and detractors.
  • How much market share you stand to gain by converting detractors into promoters.
  • Which messages promoters, passives and detractors associate with your brand.
  • Your brand DNA: what doctors really think of your brand-in their own words.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:

  • Detractors are those who answer 0 - 6.
  • Passives are those who answer 7 - 8.
  • Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors' own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Back to Top